Centrient Holding BV (DSPPHA) EUR600m 144A/Reg S sr sec notes 2-part. B2/B (stable/stable). Via Citi (B&D)/MS jt glocos and jt physical books/ABN AMRO/GS/Jefferies/Mizuho/Rabo/RBC jt books. No reg rights. List ISE. NY law. Settlement 05/19.
- EUR300m sr sec fixed-rate notes due 05/05/30 (5y). NC2 (05/15/27) (MWC B+50bp), then at 103.375, 101.6875, 100. Equity claw: 2y 40% at 106.75. Special call: 10% per year the 1st 2 years at 103. CoC at 101. Reg S ISIN: XS3045391607. IPT: mid-to-high 7s. Price talk: 7.25%-7.50%. Revised price talk: 7.00%-7.125%. Final terms: EUR300m at 6.75%. Priced: 6.75% at 100. +451bp vs DBR 0% 08/15/30.
- EUR300m sr sec FRN due May 05/05/30 (5y). NC1 (MWC B+50bp). then at 100. CoC at 101. Quarterly pay. Reg S ISIN: XS3045393306. IPT: E+475bp at 98.50-99.00. Price talk: E+475bp at 99.00-99.50. Revised price talk: E+450bp at 99.50-99.75. Final terms: EUR300m E+450bp at par. Priced: 3mE+450bp at 100.
Roadshow (small group meetings) 05/12-13 (investor call at 11am UKT 05/12). Books closed at 3:30pm (from 3pm) UKT 05/13. Reconfirms were due 4:45pm UKT 05/13. UOP: refinance its EUR515m 1st lien term loan B due 2027 and EUR83m 2nd lien term loan due 2028. Equity sponsor: Bain. Biz: B2B pharma developer and manufacturer of intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms. HQ: Rotterdam, Netherlands.
Netroadshow link: https://www.netroadshow.com/ev...;confId=82536